Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|13|7|970-983

ISSN： 1389-4501

Source： Current Drug Targets, Vol.13, Iss.7, 2012-06, pp. : 970-983

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

By Forst Thomas   Pfützner Andreas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 101-110

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

By Ahrén Bo  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 431-442

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg-10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

By Retlich Silke  

Clinical Pharmacokinetics, Vol. 49, Iss. 12, 2010-12 ,pp. : 829-840

Adis International

Access to resources Recommend Favorite

Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 13, 2012-11 ,pp. : 1345-1358

Bentham Science Publishers

Access to resources Recommend Favorite

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A   Lamos Elizabeth M   Davis Stephen N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite